Starling Oncology reports third quarter 2026 financial results
Revenue rises 24.3% to $169.8 million and Adjusted EBITDA turns positive at $3.4 million; the company affirms its full-year 2026 guidance.
See the latest news and media coverage for Starling Oncology. We track all announcements, press releases, and industry mentions in real time, all in one place.
Community-based cancer care provider
starlingoncology.comLast updated
In short: Starling Oncology reported 24.3% revenue growth, positive adjusted EBITDA and reaffirmed 2026 guidance.
Revenue rises 24.3% to $169.8 million and Adjusted EBITDA turns positive at $3.4 million; the company affirms its full-year 2026 guidance.
The clinic at 588 Sterthaus Drive in Ormond Beach offers personalized, evidence-based cancer care with advanced treatment and ongoing support, open weekdays.
It will report on Thursday, November 5, 2026, and hold a conference call at 5:00 p.m. ET, with a live webcast and replay available.
The November 12, 2021 merger with DFP Healthcare Acquisition Corp determines shareholders' basis under IRC sections 354, 356, 358 and 368.
Starling Oncology Inc. company facts, information and financial ratios from MarketWatch.
Company's proprietary platform brings clinical decision support and evidence-based pathways into one streamlined oncology workflow CERRITOS, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE)-- Starling Oncology™ Inc...
Formerly known as The Oncology Institute, Starling Oncology offers cutting-edge, evidence-based cancer care to a population of approximately 2.2 million patients including clinical trials, transfusions...
Company to begin trading on Nasdaq under new ticker symbol “STLN,” replacing “TOI”...
Track Starling Oncology and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.